CYPHERPUNK TECHNOLOGIES INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.00%, a 12.36% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.56%, a 113.17% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.67%, a 153.03% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.66%.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.90%, a 2.09% increase from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.82%, a 5.68% decline from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.05%, a 30.65% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.10%, a 278.05% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 3.90% 10-K · filed 2026-03-16 | |||||
| 2024-12-31 | 3.82% 10-K · filed 2026-03-16 | |||||
| 2024-09-30 | 3.98% 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 4.00% 10-Q · filed 2025-08-14 | |||||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-13 | |||||
| 2023-12-31 | 4.05% 10-K · filed 2025-03-26 | |||||
| 2023-09-30 | 4.05% 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | 3.57% 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | 3.56% 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | 3.10% 10-K · filed 2024-03-18 | |||||
| 2022-09-30 | 3.06% 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | 1.82% 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | 1.67% 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | 0.82% 10-K · filed 2023-03-24 | |||||
| 2021-09-30 | 0.81% 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 0.80% 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | 0.66% 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | 0.66% 10-K · filed 2022-03-11 | |||||
| 2020-09-30 | 0.66% 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | 0.79% 10-Q · filed 2021-08-13 | |||||
| 2019-12-31 | 2.07% 10-K · filed 2021-03-12 | |||||
| 2019-09-30 | 2.07% 10-Q · filed 2019-11-14 | |||||
| 2019-06-30 | 2.08% 10-Q · filed 2019-08-09 | |||||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-14 | 2.55% 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | 0.00% 10-Q · filed 2020-05-14 | 2.80% 10-Q · filed 2019-05-15 | ||||
| 2018-09-30 | 2.80% 10-Q · filed 2018-11-09 | |||||
| 2018-06-30 | 2.80% 10-Q · filed 2018-08-08 | |||||
| 2018-03-31 | 2.10% 10-Q/A · filed 2018-08-08 | |||||
| 2017-12-31 | 2.10% 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |